Galleri Test: An Effective, Proactive Tool for Early Cancer Detection

Cancer remains a leading cause of death worldwide, in part because many cancers develop silently, often progressing before symptoms even appear. Traditional screening has helped reduce mortality for some cancers, like breast and colon, but over 70% of cancer deaths are caused by cancers with no recommended screening test.

At Griffin Concierge Medical, the GRAIL Galleri® test is a multi-cancer early detection tool that screens for a signal associated with 50+ types of cancer through a single blood draw performed in their office.

Finding cancer before it causes symptoms can allow for more treatment options and better outcomes. Many of the cancers rising in incidence—pancreatic cancer, liver cancer, and some gastrointestinal cancers—are ones for which good routine screening doesn't yet exist.

Recent data from the PATHFINDER 2 study showed that when Galleri was added to existing U.S. Preventive Services Task Force recommended screenings, the number of cancers found within a year increased by more than seven-fold.

When Galleri was layered on top of breast, cervical, colorectal, lung, and prostate screenings, it detected approximately three times as many cancers as standard screening alone—with about three-quarters of those cancers having no standard-of-care screening option.

More than half of the new cancers detected were stage I or II, and nearly 70% were stage I–III, underscoring the potential impact of finding cancer earlier.

Galleri is a simple blood test designed to detect a shared cancer signal. It is not meant to diagnose cancer; its primary function is to detect a signal that could indicate cancer is present, often before symptoms appear. If a signal is detected, the test predicts the cancer signal origin (CSO) and helps guide follow-up diagnostics.

The Galleri test screens for 50+ types of cancer, including pancreatic cancer, ovarian cancer, stomach cancer, liver cancer, kidney cancer, esophageal cancer, and certain blood cancers.

In the PATHFINDER 2 study, Galleri demonstrated 99.6% specificity, corresponding to a false-positive rate of just 0.4%, meaning it rarely signaled cancer when none was present.

For all cancers combined, episode sensitivity in PATHFINDER 2 was 40.4%. When a cancer signal was detected, the test correctly identified the Cancer Signal Origin about 92% of the time. For pancreatic cancer, sensitivity was approximately 83.7%.

Even with these encouraging results, Galleri does not detect every cancer. A negative result does not guarantee that you are cancer-free. It is used alongside standard screenings and clinical context as an additional tool.

Generally, Galleri is intended for adults with elevated cancer risk—typically age 50 or older, those with family history or genetic predisposition, people with past exposure risks, or anyone wanting more proactive screening coverage. The test is not recommended for individuals under 22, those pregnant, or people currently being treated for cancer.

At Griffin Concierge Medical, Galleri is not a replacement for existing cancer screening tests, but a powerful enhancement integrated into a comprehensive, personalized strategy.

Griffin combines Galleri with standard screenings, non-invasive stool and liquid biopsy screenings through partnerships, and considers whole-body MRI as an advanced, non-radiation imaging modality to complement blood-based detection.

Even with innovative tools, prevention remains the cornerstone. Griffin helps patients optimize factors that dramatically lower cancer risk: regular exercise, healthy diet, better sleep, stress management, limiting alcohol, and smoking cessation.

If a signal is detected, Griffin ensures patients are not left waiting or navigating alone, coordinating imaging and diagnostics, facilitating specialty referrals, and providing ongoing support from physicians and care teams.

Griffin's partnerships include Florida Cancer Specialists, Moffitt Cancer Center, Johns Hopkins, MD Anderson Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center.

The national price for the Galleri test is $949, but Griffin members receive an exclusive member discount.